Contraceptives Market 2021: Understanding the New Technologies in Medical Device Sector

Contraceptives prevent pregnancy by preventing sperm from entering the uterus. It is more commonly known as the birth control method used to avoid pregnancy. Various contraception is available in the market, such as male condoms, female condoms, IUDs, vaginal rings, diaphragms, and contraceptive sponges. Condoms are the only contraception that prevents sexually transmitted infections (STI).    

Bayer AG, and Merck & Co., Inc- Notable Market Players in Contraceptives Market

Market leaders operating in the market have undertaken various organic growth strategies in the contraceptives market. The contraceptives majorly consists of the players such as as Bayer AG, Cooper Companies, Inc., Merck & Co., Inc, HLL Lifecare Limited, Church & Dwight, Inc., Pregna International Limited, Mayer Laboratories, Inc., Medicines360, Prosan International B.V., and Cupid Limited among others. Some of the activities undertaken by the company, which have promoted its growth are, product launch, approvals, partnership and strategy and business planning. Companies such as Bayer AG, Cupid Limited and others have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market.  

Below is the list of the growth strategies done by the players operating in the Contraceptives  market:




Bureau of Reproductive Health, Department of Health, Ministry of Public Health, and Bayer Thai Co., Ltd., join a collaboration international campaign to reduce unplanned pregnancies among Thai teens as well as promote awareness of effective birth control methods to improve quality of life on World Contraception Day 2020


Luye Pharma Group Ltd. agreed to acquire the global rights to hormonal contraceptive Apleek from Bayer AG.


The Cooper Companies, Inc. has entered into a definitive asset purchase agreement with Teva Pharmaceutical Industries Ltd. to acquire the global rights and business of its PARAGARD Intrauterine Device (IUD) in a $1.1 billion cash transaction.


Cupid Limited, has received USFDA approval for the additional variants of Cupid male contraceptives. The company has received USFDA nod for the additional four variants to market them in the United States. Earlier, the company had received USFDA approval for one variant of male contraceptives


Leave a Reply

Your email address will not be published. Required fields are marked *